Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa
Status:
Withdrawn
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
The CAPRISA 014 trial aims to assess the safety and acceptability of the long-acting (LA)
injectable antiretroviral agent, cabotegravir LA (GSK1265744), in HIV uninfected women in
KwaZulu-Natal, South Africa.
Phase:
Phase 2
Details
Lead Sponsor:
Centre for the AIDS Programme of Research in South Africa
Collaborator:
ViiV Healthcare
Treatments:
Cabotegravir HIV Integrase Inhibitors Soybean oil, phospholipid emulsion